A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Targeted therapies have revolutionized cancer care, but pediatric malignancies like Ewing sarcoma have seen limited success due to simple tumor genomes.
• The cyclin-dependent kinase (CDK)4/6 pathway is a recent therapeutic target in Ewing sarcoma.
• Resistance to single-agent targeted therapies is a common challenge, necessitating combination strategies.

Purpose of the Study:

• To identify genes mediating resistance to CDK4/6 inhibitors in Ewing sarcoma.
• To discover biologically relevant drug combinations for Ewing sarcoma treatment.
• To explore synergistic combinations with CDK4/6 inhibitors.

Main Methods:

• Genome-scale open reading frame (ORF) screen in Ewing cell lines to identify resistance genes.
• Establishment of CDK4/6 inhibitor-resistant Ewing cell lines.
• Small-molecule screen to identify synergistic drug combinations.
• In vitro and in vivo (mouse models) evaluation of drug combinations.

Main Results:

• Overexpression of Insulin-like Growth Factor 1 Receptor (IGF1R) was identified as a mechanism of resistance to CDK4/6 inhibitors.
• Elevated phospho-IGF1R levels correlated with acquired resistance in Ewing sarcoma.
• An IGF1R inhibitor demonstrated synergy with a CDK4/6 inhibitor in vitro and in vivo.
• The combination therapy profoundly inhibited cell cycle and PI3K/mTOR signaling.

Conclusions:

• IGF1R activation represents an escape mechanism from CDK4/6 inhibition in Ewing sarcoma.
• Dual targeting of CDK4/6 and IGF1R pathways offers a synergistic combination for Ewing sarcoma.
• This combination therapy holds potential for clinical application in Ewing sarcoma.